flying bird

Tricks and Tips

free trail

free trail
free trail

Friday, 27 July 2018


CapitalStars Investment Adviser

Adani Ports signs long-term regasification pact with GAIL for Dhamra LNG terminal
Adani Ports and Special Economic Zone (APSEZ), India’s leading port infrastructure developer and part of the Adani Group, today said it had signed a long term agreement with GAIL (India) Ltd, the state run gas company, to provide Liquefied Natural Gas (LNG) regasification services on a use or pay basis, at its upcoming LNG import terminal at Dhamra in Odisha.
As per the contract, GAIL India has booked 1.5MT per annum (MTPA) regasification capacity for a period of 20 years. GAIL plans to supply the gas to its portfolio of customers located in the eastern region and along the under development Jagdishpur–Haldia gas grid.

Hindalco soars 4% after its unit buys Aleris for $2.6bn
Shares of Kumar Mangalam Birla-led Hindalco soared over 4.5% after the company announced that it would be acquiring US-based Aleris via its US subsidiary Novelis at an enterprise value of $2.58bn. The announcement was made post market hours on Thursday.
The break-down of the deal stands at $775mn in cash for equity, while the remainder would be the debt that is currently held on Aleris’ books.

Idea surges 4% post DoT’s approval for Vodafone India merger
Idea Cellular spurted nearly 4% in early morning trade today post Department of Telecommunication's approval of its merger with Vodafone India (VIL) and Vodafone Mobile Services (VMSL).
The merger is subject to National Company Law Tribunal (NCLT), Mumbai Bench, passing the dissolution order of VIL and VMSL, which is expected shortly, the company said in a release to the exchange today.

Biocon up 9% over solid Q1 numbers
Shares of Biocon are up 9% intraday over its better-than-expected earnings posted yesterday. The Bengaluru based Biotech company reported 21.2% yoy growth in revenue to Rs1, 123.8cr. EBITDA and grew by 23.8% and 47.2% yoy. EBITDA margins were at 21.2% in Q1FY19. The result was much ahead of the street estimates, which has brought back the investor’s confidence in the stock.

Lupin launches generic Desoximetasone Topical Spray in US
Pharma major Lupin on Friday launched generic Desoximetasone Topical Spray, 0.25%, in the United States after receiving approval from the United States Food and Drug Administration (USFDA). The spray is the generic equivalent of Taro Pharmaceuticals USA’s Topicort Topical Spray, 0.25%.
The spray is used to treat plaque psoriasis in patients 18 years or older. It had annual sales of ~$18.7mn in the US, the drugmaker said, citing IQVIA MAT May 2018 data.


Post a Comment